Investigational Drugs 

Originally presented at HOPA's 13th Annual Conference, March 2017.

Genomic-Enabled Brain Tumor Therapeutics

This session will delineate the role of an oncology clinical pharmacist on a Molecular Tumor Board. The elements and sequence of events that lead to a treatment recommendation will be illustrated, followed by a presentation of the finding and results from the first precision medicine study in patients with recurrent GBM. New actionable targets will be identified that are modulated by our currently available pharmacopeia.

Learning Objectives

  • Describe the components of a therapeutic recommendation based on molecular defined actionable targets in glioblastoma multiforme (GBM).
  • Identify U.S. Food and Drug Administration–approved drugs that target common molecularly altered genes or pathways in GBM.


John Kuhn, PharmD FCCP

John Kuhn received his BS degree in pharmacy in 1972 from the University of Texas (UT) College of Pharmacy. He earned his PharmD degree in 1977 through a joint program of the UT College of Pharmacy and the UT Health Science Center, San Antonio, TX. He is professor of translational oncology at the UT College of Pharmacy and is currently a member of the IVY Foundation Early Phase Clinical Trials Consortium testing the feasibility of using molecular profiling to guide an individualized treatment plan in adults with recurrent or progressive glioblastoma.

Activity type

Research; Patient Management & Therapeutics

“Basket Trials”: An Exciting New Era in Cancer Treatment

This session will discuss basket trials as a new clinical trial design in cancer treatment. Traditional clinical trials focus on a particular cancer type, but basket studies concentrate on a specific mutation found in the tumor, regardless of where the cancer originated. Basket studies provide an important opportunity to test therapies for rare cancers, including pediatric cancers. This session will summarize two ongoing basket trials in pediatric and adult cancers, briefly explain the scientific rationale of these trials, and discuss the potential roles of clinical pharmacists in a basket trial clinic.

Learning Objectives

  • Explain the difference between biomarker selected basket studies and other early-phase cancer clinical trials.
  • Discuss how basket trials can benefit both pediatric and adult patients with cancer.
  • Identify potential roles of the clinical pharmacists at an outpatient basket trials clinic.


Dazhi Liu, PharmD BCOP

Dazhi Liu received her PharmD degree from the University of Iowa and completed a PGY-1 residency at Cincinnati Children’s Hospital Medical Center and a PGY-2 residency in pediatric oncology at Memorial Sloan Kettering Cancer Center (MSKCC). She worked as a clinical pharmacy specialist in pediatric oncology at MSKCC and in August 2016 joined the Developmental Therapeutic Clinic (a basket trial clinic) there, which offers her the opportunity to work with internally and externally recognized clinicians to conduct cutting-edge clinical trials of new therapies for a variety of cancers.

Activity type

Research; Patient Management & Therapeutics

Accreditation Statement

logo acpe

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.

This activity has been approved for .1 CEU

This course is also included as part of the Best of AC17 Bundle product.

Release Date: August 31, 2017

Expiration Date: March 29, 2020

Member: $25

Non-Member: $35

Purchase Now